Trial Profile
Immune response in the sentinel node in melanoma patients after the pre-operative administration of immune modulators GM-CSF and / or CpG 7909
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Jul 2017
Price :
$35
*
At a glance
- Drugs Agatolimod (Primary) ; Sargramostim (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 04 Aug 2016 Status changed from active, no longer recruiting to completed.
- 26 Jul 2016 New trial record